Hemogenyx Pharmaceuticals Financials
HEMO Stock | 343.40 20.90 6.48% |
Return On Equity (1.56) |
Hemogenyx | Select Account or Indicator |
Understanding current and past Hemogenyx Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Hemogenyx Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Hemogenyx Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Hemogenyx Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Hemogenyx Pharmaceuticals PLC. Check Hemogenyx Pharmaceuticals' Beneish M Score to see the likelihood of Hemogenyx Pharmaceuticals' management manipulating its earnings.
Hemogenyx Pharmaceuticals Stock Summary
Hemogenyx Pharmaceuticals competes with Toyota, SoftBank Group, OTP Bank, Public Service, and Baker Hughes. Hemogenyx Pharmaceuticals is entity of United Kingdom. It is traded as Stock on LSE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | UK Stock View All |
Exchange | London Exchange |
ISIN | GB00BYX3WZ24 |
Business Address | 60 Gracechurch Street, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | hemogenyx.com |
Phone | 44 79 0917 7311 |
You should never invest in Hemogenyx Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Hemogenyx Stock, because this is throwing your money away. Analyzing the key information contained in Hemogenyx Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Hemogenyx Pharmaceuticals Key Financial Ratios
There are many critical financial ratios that Hemogenyx Pharmaceuticals' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Hemogenyx Pharmaceuticals reports annually and quarterly.EBITDA | (5.73 M) | ||||
Net Income | (6.69 M) | ||||
Total Asset | 6.11 M | ||||
Retained Earnings | (23.8 M) |
Hemogenyx Pharmaceuticals Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.0M | 2.7M | 8.5M | 7.1M | 6.1M | 3.5M | |
Net Debt | 758.6K | (184.2K) | (6.8M) | 890.1K | 1.7M | 1.8M | |
Retained Earnings | (6.0M) | (8.0M) | (13.1M) | (17.1M) | (23.8M) | (22.6M) | |
Cash | 498.7K | 1.8M | 6.8M | 2.5M | 1.2M | 1.9M | |
Other Current Assets | 55.8K | 105.0K | 298.2K | 62.0K | 922.0K | 968.1K | |
Total Current Assets | 554.5K | 1.9M | 7.1M | 2.6M | 2.2M | 2.1M | |
Common Stock | 3.6M | 3.6M | 4.3M | 9.8M | 11.8M | 12.3M | |
Other Current Liab | 80.3K | 47.5K | 46.9K | 51.9K | 77.3K | 71.2K | |
Net Tangible Assets | 686.4K | (608.6K) | 635.9K | 7.8M | 8.9M | 9.4M | |
Accounts Payable | 61.4K | 113.2K | 295.8K | 374.3K | 301.7K | 154.9K | |
Total Liab | 1.4M | 1.8M | 352.8K | 3.8M | 3.3M | 3.5M | |
Intangible Assets | 272.8K | 262.1K | 255.0K | 441.5K | 470.2K | 356.6K | |
Net Receivables | 32.3K | 56.3K | 7.5K | 9.8K | 5.1K | 4.9K | |
Net Invested Capital | 797.6K | 2.5M | 8.2M | 3.3M | 2.8M | 3.4M | |
Net Working Capital | 372.9K | 138.4K | 6.8M | 1.8M | 1.5M | 2.2M |
Hemogenyx Pharmaceuticals Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 31.3K | 33.2K | 2.6M | 33.0 | 316.0K | 365.3K | |
Operating Income | (1.7M) | (2.2M) | (2.7M) | 4.0M | (6.5M) | (6.1M) | |
Ebit | (1.5M) | (2.1M) | (2.5M) | (4.0M) | (6.4M) | (6.1M) | |
Ebitda | (1.4M) | (2.0M) | (2.4M) | (3.4M) | (5.7M) | (5.4M) | |
Income Before Tax | (1.5M) | (2.1M) | (5.1M) | (4.0M) | (6.7M) | (6.4M) | |
Net Income | (1.5M) | (2.1M) | (7.5M) | (4.3M) | (6.7M) | (6.4M) | |
Gross Profit | (421.8K) | (350.7K) | (283.6K) | (2.6M) | (645.7K) | (678.0K) | |
Income Tax Expense | (35K) | 20.4K | 2.4M | 361.2K | (5.8K) | (5.5K) | |
Interest Income | 14.2K | 3.4K | 18.0K | 10.6K | 85.3K | 89.6K | |
Research Development | 21.25 | 83.66 | 37.58 | 402.94 | 90.6K | 95.2K | |
Cost Of Revenue | 421.8K | 350.7K | 283.6K | 2.6M | 645.7K | 653.2K | |
Net Interest Income | (17.1K) | (29.9K) | (2.6M) | 10.6K | (230.6K) | (242.2K) |
Hemogenyx Pharmaceuticals Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (1.3M) | 1.3M | 5.0M | (4.3M) | (1.3M) | (1.2M) | |
Free Cash Flow | (1.2M) | (2.0M) | (3.4M) | (3.3M) | (6.2M) | (5.9M) | |
Capital Expenditures | 11.9K | 173.0K | 818.0K | 428.9K | 117.3K | 180.2K | |
Net Income | (1.5M) | (2.1M) | (5.1M) | (4.0M) | (6.7M) | (6.4M) | |
End Period Cash Flow | 498.7K | 1.8M | 6.8M | 2.5M | 1.2M | 1.9M | |
Other Non Cash Items | 17.1K | 30.0K | 2.1M | 621.0K | 772.8K | 663.1K | |
Investments | 2.3K | (169.7K) | (939.0K) | (420.3K) | (31.9K) | (33.5K) | |
Net Borrowings | 1.2M | (39.4K) | 420.5K | (3.2M) | (2.9M) | (2.8M) | |
Depreciation | 94.7K | 106.8K | 126.3K | 195.2K | 645.7K | 678.0K | |
Change To Netincome | 157.9K | 233.6K | 2.2M | 630.9K | 725.5K | 845.2K |
Hemogenyx Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hemogenyx Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Hemogenyx Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hemogenyx Pharmaceuticals competition to find correlations between indicators driving Hemogenyx Pharmaceuticals's intrinsic value. More Info.Hemogenyx Pharmaceuticals PLC is rated # 4 in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hemogenyx Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Hemogenyx Pharmaceuticals Systematic Risk
Hemogenyx Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Hemogenyx Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Hemogenyx Pharmaceuticals correlated with the market. If Beta is less than 0 Hemogenyx Pharmaceuticals generally moves in the opposite direction as compared to the market. If Hemogenyx Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Hemogenyx Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Hemogenyx Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Hemogenyx Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Hemogenyx Pharmaceuticals PLC Total Assets Over Time
Hemogenyx Pharmaceuticals December 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Hemogenyx Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Hemogenyx Pharmaceuticals PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of Hemogenyx Pharmaceuticals PLC based on widely used predictive technical indicators. In general, we focus on analyzing Hemogenyx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Hemogenyx Pharmaceuticals's daily price indicators and compare them against related drivers.
Information Ratio | (0.07) | |||
Maximum Drawdown | 49.08 | |||
Value At Risk | (10.70) | |||
Potential Upside | 13.33 |
Additional Tools for Hemogenyx Stock Analysis
When running Hemogenyx Pharmaceuticals' price analysis, check to measure Hemogenyx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemogenyx Pharmaceuticals is operating at the current time. Most of Hemogenyx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hemogenyx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemogenyx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hemogenyx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.